Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend (12mg)
$64.00 - $43.00
Fragment 176-191, Mod GRF 1-29, & Ipamorelin Peptide Blend
This product is a 12mg blend of three high-purity peptides: Fragment 176-191 (6mg), Mod GRF 1-29 (3mg), and Ipamorelin (3mg). Provided as a lyophilized powder with a certified purity of >99%, it is ideal for research applications. The SKU is P-FRAGMODIPAM-12.
Pricing and Discounts
5-8 units: A 5% discount is applied, with a price of $69.35 per unit.
9+ units: A 10% discount is applied, with a price of $65.70 per unit.
We offer FREE shipping on all orders over $200.
Component Peptides π§ͺ
Modified GRF 1-29 (Mod GRF 1-29): This peptide is a modified version of Growth Hormone-Releasing Hormone (GHRH). Its amino acid modifications make it more stable and resistant to enzymatic degradation, potentially increasing its half-life. It is posited to work by activating GHRH receptors in the pituitary gland, which may trigger the release of growth hormone.
Ipamorelin: A synthetic pentapeptide, Ipamorelin is a growth hormone secretagogue receptor (GHSR) agonist. It's researched for its potential to activate ghrelin receptors, leading to the synthesis and release of growth hormone from the anterior pituitary gland. Research also suggests it may influence appetite.
Fragment 176-191: This is a fragment of the human growth hormone molecule, often called the "fat-burning peptide." It is a subject of research for its potential to induce weight loss, possibly by targeting beta-3 adrenergic receptors and enhancing fat oxidation and energy expenditure.
Key Research Areas π§¬
1. Lipolytic Action
Research on obese murine models suggests that Fragment 176-191 may lead to a significant reduction in body weight and excess fat. While the peptide is thought to increase the expression of beta-3 adrenergic receptors (Γ3-AR), some studies indicate it may also promote fat burning through other mechanisms, such as increased energy expenditure, and not rely solely on these receptors. A clinical trial with obese subjects suggested a reduction in body weight and improved cholesterol profiles.
2. Pituitary Gland and Growth Hormone
Mod GRF 1-29 and Ipamorelin are a focus of research for their potential to act on the pituitary gland to release growth hormone.
Ipamorelin is thought to activate the GHS-R1a receptor, leading to an influx of calcium ions and the subsequent release of growth hormone from somatotroph cells.
Mod GRF 1-29 is thought to bind to GHRH receptors, initiating a cascade that results in the conversion of ATP to cAMP, activating protein kinase A (PKA) and ultimately leading to the release of growth hormone.
The combination of these two peptides is posited to have a synergistic effect, amplifying the release of growth hormone.
3. Regeneration
A study on rabbits with knee cartilage damage suggested that Fragment 176-191, especially when combined with hyaluronic acid, may enhance cartilage regeneration and repair. The combination appeared to be more effective than either substance alone.
4. Bone Mineralization and Appetite
Preliminary research suggests that Ipamorelin may have the potential to improve bone mineralization and increase bone mineral content. Additionally, due to its potential to activate ghrelin receptors, Ipamorelin has been explored for its potential to increase appetite, which may lead to weight gain.
Product Specifications π
Molecular Formula:
Fragment 176-191: C78βH125βN23βO23βS2β
Mod GRF 1-29: C152βH252βN44βO42β
Ipamorelin: C38βH49βN9βO5β
Molecular Weight:
Fragment 176-191: 1817.12 g/mol
Mod GRF 1-29: 3367.9 g/mol
Ipamorelin: 711.8 g/mol
Important Notice: The Fragment 176-191 & Modified GRF 1-29 & Ipamorelin peptide blend is available for research and laboratory purposes only. It is not intended for human or veterinary use. All information provided is for educational and scientific reference only and has not been evaluated by the FDA or any medical regulatory body.